Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein

Biochemical Pharmacology

Volumn 55, Issue 12, 1998, Pages 1947-1954

  Snowden, Andrew W ^a   Perkins, Neil D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer; Chromatin; Differentiation; Gene expression; p21; Transcription

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1;

CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CHROMATIN; DNA DAMAGE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

EID: 0032525913     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00020-3     Document Type: Article

References (90)

1. Tjian R, Maniatis T. Transcriptional activation A complex puzzle with few easy pieces . Cell. 77:1994;5-8.
2. Orphanides G, Lagrange T, Reinberg D. The general transcription factors of RNA polymerase II. Genes Dev. 10:1996;2657-2683.
3. Yee SP, Branton PE. Detection of cellular proteins associated with human adenovirus type-5 early region-1A polypeptides. Virology. 147:1985;142-153.
4. Arany Z, Sellers WR, Livingston DM, Eckner R. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell. 77:1994;799-800.
5. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8:1994;869-884.
6. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature. 365:1993;855-859.
7. Yuan W, Condorelli G, Caruso M, Felsani A, Giordano A. Human p300 protein is a coactivator for the transcription factor MyoD. J Biol Chem. 271:1996;9009-9013.
8. Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, Giordano A, Levrero M. p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. EMBO J. 16:1997;369-383.
9. Eckner R, Yao T, Oldread E, Livingston DM. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev. 10:1996;2478-2490.
10. Dai P, Akimaru H, Tanaka Y, Hou D-X, Yasukawa T, Kanei-Ishii C, Takahashi T, Ishii S. CBP as a transcriptional coactivator of c-Myb. Genes Dev. 10:1996;528-540.
11. Oelgeschläger M, Janknecht R, Krieg J, Schreek S, Lüscher B. Interaction of the co-activator CBP with Myb proteins Effects on Myb-specific transactivation and on the cooperativity with NF-M . EMBO J. 15:1996;2771-2780.
12. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE Jr. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc Natl Acad Sci USA. 93:1996;15092-15096.
13. Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen T, Rose DW, Rosenfeld MG, Glass CK. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA. 94:1997;1074-1079.
14. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, Dandrea A, Livingston DM. Cooperation of Stat2 and p300/CBP in signaling induced by interferon-α Nature. 383:1996;344-347.
15. 12S have a homologous activation domain regulated by RB and CBP. Proc Natl Acad Sci USA. 93:1996;1439-1442.
16. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89:1997;1175-1184.
17. Gu W, Shi XL, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature. 387:1997;819-823.
18. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:1997;823-827.
19. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S, Heymann RA, Rose DW, Glass CK, Rosenfeld MG. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 85:1996;403-414.
20. Hanstein B, Eckner R, Direnzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA. 93:1996;11540-11545.
21. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon T, Montminy M, Evans RM. Role of CBP/p300 in nuclear receptor signalling. Nature. 383:1996;99-103.
22. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 387:1997;677-684.
23. Bannister AJ, Kouzarides T. CBP-induced stimulation of c-Fos activity is abrogated by E1A. EMBO J. 14:1995;4758-4762.
24. Bannister AJ, Oehler T, Wilhelm D, Angel P, Kouzarides T. Stimulation of c-Jun activity by CBP c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro . Oncogene. 11:1995;2509-2514.
25. Lee JS, Galvin KM, See RH, Eckner R, Livingston D, Moran E, Shi Y. Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. Genes Dev. 9:1995;1188-1198.
26. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science. 275:1997;523-527.
27. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA. 94:1997;2927-2932.
28. Janknecht R, Hunter T. Transcriptional control Versatile molecular glue . Curr Biol. 6:1996;951-954.
29. Shikama N, Lyon J, La Thangue NB. The p300/CBP family Integrating signals with transcription factors and chromatin . Trends Cell Biol. 7:1997;230-236.
30. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol. 9:1997;222-232.
31. Nakajima T, Uchida C, Anderson SF, Lee C, Hurwitz J, Parvin JD, Montminy M. RNA helicase A mediates association of CBP with RNA polymerase II. Cell. 90:1997;1107-1113.
32. Kee BL, Arias J, Montminy MR. Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator. J Biol Chem. 271:1996;2373-2375.
33. Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, Roberts SG, Green MR, Goodman RH. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature. 370:1994;223-226.
34. Abraham SE, Lobo S, Yaciuk P, Wang HH, Moran E. p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. Oncogene. 8:1993;1639-1647.
35. Dallas PB, Yaciuk P, Moran E. Characterization of monoclonal antibodies raised against p300 Both p300 and CBP are present in intracellular TBP complexes . J Virol. 71:1997;1726-1731.
36. Bannister AJ, Kouzarides T. The CBP coactivator is a histone acetyltransferase. Nature. 384:1996;641-643.
37. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959.
38. Yang X, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature. 382:1996;319-324.
39. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai M, O'Malley BW. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 389:1997;194-198.
40. Jenster G, Spencer TE, Burcin MM, Tsai SY, Tsai M, O'Malley BW. Steroid receptor induction of gene transcription A two-step model . Proc Natl Acad Sci USA. 94:1997;7879-7884.
41. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 90:1997;569-580.
42. Wolffe AP, Pruss D. Targeting chromatin disruption Transcription regulators that acetylate histones . Cell. 84:1996;817-819.
43. Wade PA, Pruss D, Wolffe AP. Histone acetylation Chromatin in action . Trends Biochem Sci. 22:1997;128-132.
44. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the C-terminal domain. Cell. 90:1997;595-606.
45. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H. Acetylation of general transcription factors by histone acetyltransferases. Curr Biol. 7:1997;689-692.
46. Janknecht R, Nordheim A. Regulation of the c-fos promoter by the ternary complex factor Sap-1a and its coactivator CBP. Oncogene. 12:1996;1961-1969.
47. Janknecht R, Nordheim A. MAP kinase-dependent transcriptional coactivation by Elk-1 and its cofactor CBP. Biochem Biophys Res Commun. 228:1996;831-837.
48. rsk. Cell. 86:1996;465-474.
49. Pines J. p21 inhibits cyclin shock. Nature. 369:1994;520-521.
50. Peter M, Herskowitz I. Joining the complex Cyclin-dependent kinase inhibitory proteins and the cell cycle . Cell. 79:1994;181-184.
51. Hunter T, Pines J. Cyclins and cancer II Cyclin D and CDK inhibitors come of age . Cell. 79:1994;573-582.
52. 1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
53. Yaciuk P, Moran E. Analysis with specific polyclonal antiserum indicates that the E1A-associated 300-kDa product is a stable nuclear phosphoprotein that undergoes cell cycle phase-specific modification. Mol Cell Biol. 11:1991;5389-5397.
54. Banerjee AC, Recupero AJ, Mal A, Piotrkowski AM, Wang DM, Harter ML. The adenovirus E1A 289R and 243R proteins inhibit the phosphorylation of p300. Oncogene. 9:1994;1733-1737.
55. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, Smith JR. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog. 11:1994;59-64.
56. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:1995;935-944.
57. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 9:1994;3389-3396.
58. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:1994;3391-3395.
59. Jiang H, Lin J, Su Z, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 9:1994;3397-3406.
60. Eck SL, Perkins ND, Carr DP, Nabel GJ. Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-κB in vivo. Mol Cell Biol. 13:1993;6530-6536.
61. Devary Y, Rosette C, DiDonato JA, Karin M. NF-κB activation by ultraviolet light is not dependent on a nuclear signal. Science. 261:1993;1442-1445.
62. Wang C, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis Potentiation by inhibition of NF-κB . Science. 274:1996;784-787.
63. 1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
64. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
65. Dulić V, Kaufmann WK, Wilson SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
66. Billon N, Grunsven LA, Rudkin BB. The CDK inhibitor p21 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation in PC12 cells. Oncogene. 13:1997;2047-2054.
67. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 267:1995;1018-1021.
68. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, Dotto GP. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA. 92:1995;5451-5455.
69. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science. 267:1995;1024-1027.
70. Li C-Y, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J Biol Chem. 270:1995;4971-4974.
71. Datto MB, Hu PP-C, Kowalik TF, Yingling J, Wang X-F. The viral oncoprotein E1A blocks transforming growth factor β-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol. 17:1997;2030-2037.
72. Braun T, Buschhausen-Denker G, Bober E, Tannich E, Arnold HH. A novel human muscle factor related to but distinct from MyoD1 induces myogenic conversion in 10T1/2 fibroblasts. EMBO J. 8:1989;701-709.
73. Wright WE, Sassoon DA, Lin VK. Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD. Cell. 56:1989;607-617.
74. Edmondson DG, Olson EN. A gene with homology to the myc similarity region of MyoD1 is expressed during myogenesis and is sufficient to activate the muscle differentiation program. Genes Dev. 3:1989;628-640.
75. Lassar AB, Buskin JN, Lockshon D, Davis RL, Apone S, Hauschka SD, Weintraub H. MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer. Cell. 58:1989;823-831.
76. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science. 267:1995;1022-1024.
77. Gu W, Schneider JW, Condorelli G, Kaushal S, Mahdavi V, Nadalginard B. Interaction of myogenic factors and the retinoblastoma protein mediates muscle-cell commitment and differentiation. Cell. 72:1993;309-324.
78. Prabhu S, Ignatova A, Park ST, Sun X-H. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol. 17:1997;5888-5896.
79. Sato S, Roberts K, Gambino G, Cook A, Kouzarides T, Goding CR. CBP/p300 as a co-factor for the Microphthalmia transcription factor. Oncogene. 14:1997;3083-3092.
80. Lundblad JR, Kwok RPS, Laurance ME, Harter ML, Goodman RH. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature. 374:1995;85-88.
81. Somasundaram K, El-Deiry WS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene. 14:1997;1047-1057.
82. Eckner R, Ludlow JW, Lill NL, Oldread E, Arany Z, Modjtahedi N, DeCaprio JA, Livingston DM, Morgan JA. Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol. 16:1996;3454-3464.
83. Avantaggiati ML, Carbone M, Graessmann A, Nakatani Y, Howard B, Levine AS. The SV40 large T antigen and adenovirus E1A oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J. 15:1996;2236-2248.
84. Kwok RPS, Laurance ME, Lundblad JR, Goldman PS, Shih H, Connor LM, Marriott SJ, Goodman RH. Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP. Nature. 380:1996;642-646.
85. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong J.-M., Iwama T, Miyaki M. p300 gene alterations in colorectal and gastric carcinomas. Oncogene. 12:1996;1565-1569.
86. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RSK, Civin CI, Disteche C, Dubé I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 14:1996;33-41.
87. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider NR, Barredo JC, Cantu ES, Schlegelberger B, Behm F, Doggett NA, Borrow J, Zeleznik-Le N. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 90:1997;535-541.
88. Taki T, Sako M, Tsuchida M, Hayashi Y. The t(11;16)(p23;p13.3) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood. 89:1997;3945-3950.
89. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9:1995;650-662.
90. Houglum K, Lee KS, Chojkier M. Proliferation of hepatic stellate cells is inhibited by phosphorylation of CREB on serine 133. J Clin Invest. 99:1997;1322-1328.